로딩 중…
지수 로딩 중…
HLB Therapeutics Co.,Ltd.
115450· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,903+10.00%
2026-08-04
Financials
Valuation Metrics
HLB Therapeutics Co.,Ltd.'s Market Cap is ₩1686B. At end of 2025 it was ₩2532B. Ranked #923 of 2,436 in KR market (top 38%), #440 of 1,649 on KOSDAQ (top 27%), #104 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 168.57B KRW | KR#923/2,436 Sec#104/234 |
| Revenue | 67.56B KRW | KR#1,627/2,436 Sec#107/234 |
| Net Income | -9.57B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 229.36B KRW | KR#1,195/2,436 Sec#85/234 |
| Net Assets | 176.02B KRW | KR#1,006/2,436 Sec#72/234 |
| Employees | 95 | KR#1,663/2,436 Sec#130/234 |
| Value | ||
| P/B | 0.96x | KR#1,451/2,436 Sec#93/234 |
| P/S | 2.50x | KR#1,936/2,436 Sec#114/234 |
| FCF Yield | -5.61% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -5.44% | KR#1,762/2,436 Sec#130/234 |
| ROA | -4.17% | KR#1,849/2,436 Sec#137/234 |
| Op. Margin | -7.68% | KR#1,928/2,436 Sec#129/234 |
| Revenue Growth | -13.30% | KR#1,954/2,436 Sec#178/234 |
| Earnings Growth | -614.75% | KR#1,649/2,436 Sec#112/234 |
| Financial Health | ||
| Debt Ratio | 130.31% | KR#857/2,436 Sec#97/234 |
| Total Debt | 35.95B KRW | KR#1,113/2,436 Sec#83/234 |
| FCF | -9.46B KRW | KR#1,695/2,436 Sec#144/234 |
| Cash | 17.13B KRW | KR#1,336/2,436 Sec#104/234 |
| Current Ratio | 1.34x | KR#1,432/2,436 Sec#152/234 |
| Dividend | ||
| Div. Growth | -37.70% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -46.38% | KR#1,995/2,436 Sec#185/234 |
| 1M Return | -12.51% | KR#1,911/2,436 Sec#191/234 |
| From 52W High | -54.25% | KR#1,412/2,436 Sec#120/234 |
| 1Y MDD | -77.13% | KR#2,227/2,436 Sec#203/234 |
| Trading | ||
| Volume | 524,191 shares | KR#263/2,436 Sec#25/234 |
| Foreign Own. | 3.80% | KR#908/2,436 Sec#88/234 |
| Per Share | ||
| EPS | -103 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,716 KRW | KR#2,105/2,436 Sec#177/234 |
Company Info
CEO 안기홍
Employees 95
Founded 2000
HQ 경기도 성남시, KR
동사는 2000년 설립되어 2013년 코아인더스를 합병해 전자사업에 진출하고, 2014년 신약공동개발계약으로 바이오사업 기반을 마련하였음. 바이오사업은 ReGenTree와 Oblato를 통해 RGN-259와 OKN-007의 글로벌 임상을 진행하며, 콜드체인사업은 온도민감 의약품을 유통·보관·판매하고 있음. 동사는 바이오 중심 기업으로 전환을 추진하고 있으며, 다각적 사업영역 구축을 통해 지속 가능한 경영을 추구하고 있음. HLB테라퓨틱스는 2000년에 설립되었으며 경기도 성남시에 본사를 두고 있습니다.